home / stock / canf / canf articles
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenos...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Eme...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
A pivotal Phase III trial for advanced liver cancer, approved by FDA & EMA and a MASH Phase IIb are enrolling patients Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address onc...
Namodenoson demonstrated anti-fibrosis, anti-steatosis and anti-inflammatory effects in former Phase IIa study Patient enrolment for Phase IIb study is ongoing in Europe and Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipelin...
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in ha...